This site is intended for health professionals only

Wednesday 19 June 2019
Share |

Probiodrug enrols first patient in Phase II study of treatment for Alzheimer’s disease

First patient enrolled at leading Alzheimer Centre in Amsterdam

Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announced that the first patient has been enrolled in the Phase IIa “SAPHIR” clinical study of its lead product PQ912 at the Alzheimer Centre, VU Medical Centre (VUmc), Amsterdam.